Daptomycin + Vancomycin
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Staphylococcal Skin Infections
Conditions
Staphylococcal Skin Infections
Trial Timeline
Sep 9, 2011 → Oct 5, 2012
NCT ID
NCT01419184About Daptomycin + Vancomycin
Daptomycin + Vancomycin is a approved stage product being developed by Merck for Staphylococcal Skin Infections. The current trial status is completed. This product is registered under clinical trial identifier NCT01419184. Target conditions include Staphylococcal Skin Infections.
What happened to similar drugs?
3 of 4 similar drugs in Staphylococcal Skin Infections were approved
Approved (3) Terminated (2) Active (1)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01419184 | Approved | Completed |
| NCT01196169 | Approved | Terminated |
| NCT01175707 | Approved | Terminated |
| NCT00695903 | Phase 2 | Terminated |
| NCT00426933 | Phase 2 | Completed |
| NCT00295178 | Approved | Completed |
Competing Products
20 competing products in Staphylococcal Skin Infections